Insider · CIK 0001550078
Richelle P Parham
Files at BBY (BEST BUY CO INC), LH (LABCORP HOLDINGS INC.). First filing Nov 4, 2025, latest Nov 4, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
LH: LABCORP HOLDINGS INC.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 68Notable | LABCORP HOLDINGS INC. | $1.8M 7,009 shares | -74% | +20% from low-13% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 11, 2026 | LH LABCORP HOLDINGS INC. | MOption exercise Common Stock | +897 | - | - | 3,366 | Feb 13, 2026 |
| Feb 11, 2026 | LH LABCORP HOLDINGS INC. | MOption exercise Restricted Stock Unitderivative | -897 | $0.00 | $0 | 773 | Feb 13, 2026 |
| Feb 10, 2026 | LH LABCORP HOLDINGS INC. | AGrant or award Restricted Stock Unitderivative | +773 | $0.00 | $0 | 1,670 | Feb 12, 2026 |
| Oct 31, 2025 | LH LABCORP HOLDINGS INC. | SOpen-market sale Common Stock | -7,009 | $254.28 | $1.8M | 2,469 | Nov 4, 2025 |
| Jun 13, 2025 | BBY BEST BUY CO INC | AGrant or award Common Stock | +2,946 | $0.00 | $0 | 23,450 | Jun 17, 2025 |
| Feb 11, 2025 | LH LABCORP HOLDINGS INC. | AGrant or award Restricted Stock Unitderivative | +897 | $0.00 | $0 | 897 | Feb 13, 2025 |
| Feb 6, 2025 | LH LABCORP HOLDINGS INC. | MOption exercise Common Stock | +944 | - | - | 9,478 | Feb 10, 2025 |
| Feb 6, 2025 | LH LABCORP HOLDINGS INC. | MOption exercise Restricted Stock Unitderivative | -944 | $0.00 | $0 | 0 | Feb 10, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.